Sector
Healthcare
Industry
Biotechnology
Employees
36
First IPO Date
December 13, 2017
| Name | Title | Pay | Year Born |
| Oystein Soug | Chief Executive Officer | 4.59M | 1969 |
| Ramzi Amri | Chief Financial Officer | 1.86M | N/A |
| Stian Brekke | Head of Regulatory Affairs | 1.95M | N/A |
| Kristine Lofthus | Chief Production Officer | 2.1M | N/A |
| Anne-Kirsti Aksnes | Chief Clinical Officer | 2.4M | N/A |
| Gro Elisabeth Hjellum | Chief Operating Officer | 2.82M | N/A |
| Anne Cecile Alvik | Head of Quality Assurance & Employee Representative Director | 2.85M | N/A |
| Kari Myren | Chief Medical Officer | 2.97M | N/A |
| Kaja Tunhovd Johansen | Head of Quality Control | 0 | N/A |
Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a highly selective, orally administered small molecule designed to inhibit AXL. James Bradley Lorens and David R. Micklem established the company on December 21, 2007, and it is based in Bergen, Norway.